Drug Type TF Decoy |
Synonyms NDON, NF-kD-transcription-factor, NF-kappa-B decoy oligonucleotide + [19] |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 3 | - | - | |
Dermatitis, Atopic | Phase 3 | - | - | |
Dermatitis, Atopic | Phase 3 | - | - | |
Dermatitis, Atopic | Phase 3 | - | - | |
Intervertebral Disc Degeneration | Discovery | United States | 26 Feb 2018 | |
Low Back Pain | Discovery | United States | 26 Feb 2018 |
Phase 1/2 | 213 | (Phase 2 Ganitumab) | wwwoeuefql(dckzobxidp) = qwlnseyjcj gtfjabxwnr (sxazfnvnqs, iqndaqpkbu - ynpjknqpjf) View more | - | 23 Aug 2024 | ||
(Phase 2 Placebo) | wwwoeuefql(dckzobxidp) = ijkcgowngi gtfjabxwnr (sxazfnvnqs, rgjdwweixs - fchoqciokm) View more |